caplacizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5308 915810-67-2

Description:

MoleculeDescription

Synonyms:

  • caplacizumab
  • ALX-0081
  • ALX-0681
  • calibvi
  • caplacizumab-yhdp
In patients with aTTP, levels of a substance called von Willebrand factor are increased. von Willebrand factor acts on platelets to cause them to stick together and form blood clots. Caplacizumab, the active substance in Cablivi, is a nanobody (a small antibody) which has been designed to attach to von Willebrand factor in a way that stops it acting on platelets. This reduces platelets sticking together and forming clots in blood vessels and, as a result, platelet levels in the blood rise because they are no longer taken up to form clots.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
10 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Aug. 30, 2018 EMA ABLYNX NV
Feb. 6, 2019 FDA ABLYNX NV
Sept. 26, 2022 PMDA SANOFI K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
ADAMTS13 activity decreased 491.00 45.57 56 1440 142 90626809
Product use in unapproved indication 377.83 45.57 156 1340 336080 90290871
ADAMTS13 activity abnormal 230.45 45.57 23 1473 0 90626951
Epistaxis 116.55 45.57 46 1450 85079 90541872
Platelet count decreased 98.55 45.57 47 1449 136922 90490029
Off label use 61.05 45.57 82 1414 1102170 89524781
Injection site bruising 56.84 45.57 24 1472 52283 90574668

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
ADAMTS13 activity decreased 176.43 42.20 21 476 131 42620707
Product use in unapproved indication 145.38 42.20 60 437 184396 42436442
ADAMTS13 activity abnormal 103.69 42.20 10 487 0 42620838
Platelet count decreased 48.46 42.20 26 471 138555 42482283
Platelet count abnormal 44.74 42.20 10 487 3639 42617199

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
ADAMTS13 activity decreased 596.51 35.70 71 1936 258 110587034
Product use in unapproved indication 508.65 35.70 215 1792 447162 110140130
ADAMTS13 activity abnormal 297.73 35.70 30 1977 0 110587292
Epistaxis 137.19 35.70 60 1947 130312 110456980
Platelet count decreased 104.78 35.70 60 1947 230383 110356909
Platelet count abnormal 88.76 35.70 21 1986 6261 110581031
Injection site bruising 71.87 35.70 29 1978 51234 110536058
Off label use 69.72 35.70 108 1899 1500077 109087215
Gingival bleeding 45.13 35.70 16 1991 19823 110567469
Contusion 41.28 35.70 34 1973 233327 110353965
Injection site pain 38.05 35.70 29 1978 177893 110409399
Platelet count increased 37.23 35.70 15 1992 26319 110560973

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AX07 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Other antithrombotic agents
CHEBI has role CHEBI:50249 anticoagulant

Related Drugs by ATC class:

B01AX Other antithrombotic agents 3 drugs
defibrotidedermatan sulfatefondaparinux

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Thrombotic thrombocytopenic purpura indication 78129009 DOID:10772




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
von Willebrand factor Secreted ANTIBODY BINDING Kd 8.51 IUPHAR DRUG LABEL

External reference:

IDSource
2R27AB6766 UNII
4038197 VANDF
4038198 VANDF
C3713057 UMLSCUI
CHEBI:754365 CHEBI
CHEMBL2109624 ChEMBL_ID
DB06081 DRUGBANK_ID
D11160 KEGG_DRUG
9511 INN_ID
C585343 MESH_SUPPLEMENTAL_RECORD_UI
9123 IUPHAR_LIGAND_ID
784411004 SNOMEDCT_US
789447000 SNOMEDCT_US
36265 MMSL
36266 MMSL
d09171 MMSL
017896 NDDF
2110604 RXNORM

Pharmaceutical products:

None